TT
Tachyon Therapeutics develops selective small molecules that target specific cancer pathways to enhance therapeutic efficacy. The company aims to improve patient outcomes by increasing the precision of cancer treatments while minimizing side effects.
Updated 4 months ago
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Tachyon Therapeutics develops selective small molecules that target specific cancer pathways to enhance therapeutic efficacy. The company aims to improve patient outcomes by increasing the precision of cancer treatments while minimizing side effects.